News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
25,851 Results
Type
Article (3860)
Company Profile (4)
Press Release (21986)
Multimedia
Podcasts (29)
Webinars (4)
Section
Business (8798)
Career Advice (39)
Deals (1241)
Drug Delivery (19)
Drug Development (4409)
Employer Resources (12)
FDA (725)
Job Trends (1076)
News (14885)
Policy (1560)
Tag
Academia (81)
Accelerated approval (1)
Adcomms (2)
Allergies (2)
Alliances (2273)
ALS (2)
Alzheimer's disease (38)
Antibody-drug conjugate (ADC) (81)
Approvals (729)
Artificial intelligence (23)
Autoimmune disease (9)
Automation (2)
Bankruptcy (9)
Best Places to Work (846)
BIOSECURE Act (7)
Biosimilars (6)
Biotechnology (1)
Bladder cancer (19)
Brain cancer (11)
Breast cancer (69)
Cancer (479)
Cardiovascular disease (40)
Career advice (41)
Career pathing (2)
CAR-T (11)
CDC (14)
Cell therapy (21)
Cervical cancer (6)
Clinical research (3763)
Collaboration (85)
Company closure (2)
Compensation (7)
Complete response letters (7)
COVID-19 (206)
CRISPR (2)
C-suite (78)
Cystic fibrosis (2)
Data (233)
Depression (4)
Dermatology (1)
Diabetes (6)
Diagnostics (94)
Diversity, equity & inclusion (3)
Drug discovery (14)
Drug pricing (48)
Drug shortages (1)
Duchenne muscular dystrophy (6)
Earnings (2286)
Editorial (8)
Employer branding (6)
Employer resources (12)
Events (2485)
Executive appointments (90)
FDA (819)
Funding (48)
Gene editing (8)
Generative AI (4)
Gene therapy (17)
GLP-1 (82)
Government (331)
Grass and pollen (1)
Guidances (8)
Healthcare (483)
HIV (11)
Huntington's disease (2)
IgA nephropathy (3)
Immunology and inflammation (27)
Immuno-oncology (14)
Indications (9)
Infectious disease (235)
Inflammatory bowel disease (9)
Inflation Reduction Act (4)
Influenza (1)
Intellectual property (7)
Interviews (2)
IPO (373)
IRA (12)
Job creations (284)
Job search strategy (38)
JPM (9)
Kidney cancer (5)
Labor market (11)
Layoffs (64)
Leadership (1)
Legal (402)
Liver cancer (7)
Longevity (1)
Lung cancer (109)
Lymphoma (12)
Machine learning (2)
Management (4)
Manufacturing (47)
MASH (6)
Medical device (83)
Medtech (83)
Mergers & acquisitions (909)
Metabolic disorders (50)
mRNA (32)
Multiple sclerosis (14)
Neurodegenerative disease (15)
Neuropsychiatric disorders (9)
Neuroscience (83)
NextGen: Class of 2026 (199)
Non-profit (91)
Now hiring (1)
Obesity (35)
Opinion (37)
Ovarian cancer (19)
Pain (6)
Pancreatic cancer (5)
Parkinson's disease (4)
Patents (19)
Patient recruitment (8)
People (3939)
Pharmaceutical (2)
Pharmacy benefit managers (3)
Phase 1 (1081)
Phase 2 (1685)
Phase 3 (1574)
Pipeline (233)
Policy (59)
Postmarket research (201)
Preclinical (276)
Press Release (2)
Prostate cancer (6)
Psychedelics (9)
Radiopharmaceuticals (17)
Rare diseases (30)
Real estate (213)
Recruiting (4)
Regulatory (1079)
Reports (7)
Research institute (72)
Resumes & cover letters (1)
RNA editing (1)
RSV (16)
Schizophrenia (4)
Series A (13)
Series B (8)
Sickle cell disease (3)
Special edition (7)
Spinal muscular atrophy (4)
Sponsored (2)
Startups (213)
Stomach cancer (9)
Supply chain (7)
Tariffs (22)
The Weekly (27)
Vaccines (153)
Venture capital (14)
Weight loss (30)
Women's health (3)
Worklife (1)
Date
Today (5)
Last 7 days (16)
Last 30 days (62)
Last 365 days (994)
2026 (228)
2025 (1024)
2024 (1236)
2023 (1319)
2022 (2976)
2021 (2787)
2020 (2293)
2019 (1546)
2018 (1196)
2017 (1348)
2016 (1159)
2015 (1327)
2014 (867)
2013 (725)
2012 (785)
2011 (880)
2010 (816)
Location
Africa (65)
Alabama (4)
Alaska (1)
Arizona (2)
Asia (1581)
Australia (402)
California (216)
Canada (92)
China (99)
Colorado (5)
Connecticut (7)
Delaware (14)
Europe (4378)
Florida (65)
Georgia (2)
Illinois (11)
Indiana (2)
Japan (61)
Kansas (1)
Kentucky (1)
Maryland (52)
Massachusetts (252)
Michigan (1)
Minnesota (3)
Mississippi (1)
Missouri (3)
Montana (1)
Nevada (2)
New Hampshire (4)
New Jersey (290)
New York (87)
North Carolina (18)
Northern California (116)
Ohio (3)
Oregon (1)
Pennsylvania (25)
Rhode Island (4)
South America (61)
Southern California (74)
Tennessee (1)
Texas (26)
United States (1092)
Utah (8)
Virginia (8)
Washington D.C. (5)
Washington State (27)
West Virginia (1)
Wisconsin (2)
25,851 Results for "merck kgaa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
People
Sanofi Shares Decline as Paul Hudson Removed as CEO, Making Way For Merck KGaA’s Belén Garijo
The sudden departure stands in contrast to other EU pharma leaders who have been given much longer transitions in recent months, including GSK’s Emma Walmsley and Novo Nordisk’s Lars Fruergaard Jørgensen.
February 12, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
aptaTargets transferred ApTOLL to Merck KGaA, Darmstadt, Germany
ApTOLL completed a Phase 1b/2 clinical trial for acute ischemic stroke with positive results. Merck KGaA, Darmstadt, Germany, to assume clinical development and commercialization of ApTOLL.
May 22, 2025
·
1 min read
Mergers & acquisitions
Merck KGaA Moves Ahead on SpringWorks Buy for $3.9B
The transaction is expected to close in the second half of 2025. With the deal, Merck KGaA is adding to its rare disease and oncology pipelines.
April 28, 2025
·
3 min read
·
Tristan Manalac
Cardiovascular disease
Merck’s Cholesterol Pill Delivers ‘Antibody-Like Efficacy’ After Earning FDA Voucher
Merck is eyeing a quick review for its lipid-lowering drug candidate enlicitide, which in December was awarded a Commissioner’s National Priority Voucher.
March 31, 2026
·
2 min read
·
Tristan Manalac
Patents
Merck’s Keytruda Likely Has a Few Extra Years of Dominance, With Billions on the Line
Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts Bloomberg Intelligence, translating to some $22 billion more in revenue.
February 24, 2026
·
3 min read
·
Annalee Armstrong
Mergers & acquisitions
Merck To Buy Terns, ‘Unprecedented’ Leukemia Drug for $6.7B as Keytruda Cliff Looms
Merck’s acquisition of Terns Pharmaceuticals follows other big-ticket purchases, including of Verona Pharma and Cidara Therapeutics, as the pharma prepares for the impending expiration of its blockbuster’s patents.
March 25, 2026
·
3 min read
·
Tristan Manalac
Mergers & acquisitions
Merck KGaA Courts Cancer Biotech SpringWorks for Potential Buyout
Following an initial report from
Reuters
, Merck KGaA confirmed that it is in talks with SpringWorks for a potential acquisition, though details of its offer have yet to be revealed.
February 11, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Flex and Merck KGaA, Darmstadt, Germany, Win 2025 PDA Drug Delivery Innovation Award
November 14, 2025
·
2 min read
Bladder cancer
Merck, Pfizer’s Drug Combo ‘Rewrites the Standard of Care’ in Bladder Cancer
A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with muscle-invasive bladder cancer, even those eligible for cisplatin treatment.
March 2, 2026
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Merck Pushes Winrevair Past Dose-Response Doubts Into Pivotal Study for Rare Type of Heart Failure
The lack of a dose-response effect could be due to the high number of dropouts in the higher-dose Winrevair arm and the relatively small study population, a discussant for Merck explained.
March 30, 2026
·
2 min read
·
Tristan Manalac
1 of 2,586
Next
